-+ 0.00%
-+ 0.00%
-+ 0.00%

Satellos says FDA grants Fast Track designation for Duchenne drug SAT-3247

PUBT·06/29/2026 11:01:13
Listen to the news
Satellos says FDA grants Fast Track designation for Duchenne drug SAT-3247
  • FDA granted Fast Track designation to Satellos Bioscience’s SAT-3247 for Duchenne muscular dystrophy.
  • Phase 2 BASECAMP and TRAILHEAD trials remain underway, with additional data expected in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290700PRIMZONECNPR____9753633) on June 29, 2026, and is solely responsible for the information contained therein.